START1
- Recommended starting dose of JAKAFI XR: 22 mg orally once daily
- Evaluate blood parameters before and during treatment with JAKAFI XR
- JAKAFI XR is dosed orally and can be administered with or without food
- Patients must swallow JAKAFI XR tablets whole. Do not split, chew, or crush tablets
MONITOR1
- Dose modifications should be considered based on monitoring complete blood count (CBC), including platelet counts, absolute neutrophil count (ANC), hemoglobin, and bilirubin; treatment interruption and restarting dosing; or other adverse reactions, as described in the Full Prescribing Information for JAKAFI XR
- If a dose is missed, patients should not take an additional dose but should take the next usual prescribed dose
OPTIMIZE1
- Doses may be modified based on safety and efficacy
- Dose reductions may be used to manage side effects: 22 mg once daily may be reduced to 11 mg once daily
- Tapering may be considered after 6 months of treatment in patients with response who have discontinued therapeutic doses of steroids
- Taper JAKAFI XR by 1 dose level approximately every 8 weeks (22 mg once daily to 11 mg once daily)
- If cGVHD signs or symptoms recur during or after the taper of JAKAFI XR, consider retreatment
- There are no data available for switching doses between JAKAFI and JAKAFI XR. Dosing should be based on indication and specific dose modifications listed in the Full Prescribing Information for each formulation. The first dose of JAKAFI XR can be administered at the next scheduled dose of JAKAFI
AVAILABLE DOSAGES
JAKAFI® (ruxolitinib) dosages
- 5 mg twice daily
- 10 mg twice daily
- 15 mg twice daily
- 20 mg twice daily
- 25 mg twice daily
JAKAFI XR dosages
- 11 mg once daily
- 22 mg once daily
- 33 mg once daily
- 44 mg once daily
- 55 mg once daily
cGVHD=chronic graft-versus-host disease.
JAKAFI XR dose modifications
View the dosing modifications for patients with cytopenias, elevated total bilirubin, hepatic or renal impairment, and when JAKAFI XR is used with strong CYP3A4 inhibitors or fluconazole.
Dose modifications for cytopenias1
Platelet count <20 × 109/L
- Reduce JAKAFI XR by 1 dose level. If resolved within 7 days, dosing may return to initial dose level
- If not resolved within 7 days, then maintain at 1 dose level lower
Neutropenia related to JAKAFI XR use
- ANC <0.75 × 109/L
- Reduce JAKAFI XR by 1 dose level; resume at initial dose level upon recovery
- ANC <0.5 × 109/L
- Hold JAKAFI XR for up to 14 days; resume at 1 dose level lower upon recovery
- May resume initial dose level when ANC is >1 × 109/L
See Full Prescribing Information for further details on dose modifications and use in special populations.
ANC=absolute neutrophil count.
Dose modifications for elevated total bilirubin1
Elevated total bilirubin
- 3-5 × ULN: Continue JAKAFI XR at 1 dose level lower until recovery. If resolved within 14 days, increase by 1 dose level (11 mg once daily); if not resolved within 14 days, maintain the reduced dose level
- >5-10 × ULN: Hold JAKAFI XR for up to 14 days until resolved; resume at current dose upon recovery. If not resolved within 14 days, resume at 1 dose level lower upon recovery
- >10 × ULN: Hold JAKAFI XR for up to 14 days until resolved; resume at 1 dose level lower upon recovery. If not resolved within 14 days, discontinue
See Full Prescribing Information for further details on dose modifications and use in special populations.
ULN=upper limit of normal.
Dose modifications for hepatic or renal impairment1
Hepatic impairment
- Mild, moderate, or severe (NCI criteria without liver GVHD): No starting dose adjustment needed
- Score 1 or 2 liver cGVHD: No starting dose adjustment needed
- Score 3 liver cGVHD: Monitor blood counts more frequently for toxicity and modify the JAKAFI XR dosage for adverse reactions if they occur
Renal impairment
- Moderate or severe: Start JAKAFI XR at 11 mg once daily
- ESRD on dialysis: Do not use JAKAFI XR
- Avoid use of JAKAFI XR in patients with ESRD (CLcr <15 mL/min) not requiring dialysis
See Full Prescribing Information for further details on dose modifications and use in special populations.
cGVHD=chronic graft-versus-host disease; CLcr=creatinine clearance; ESRD=end-stage renal disease; NCI=National Cancer Institute.
Dose modifications for concomitant use with strong CYP3A4 inhibitors or fluconazole1
Starting dose for patients with cGVHD
- Fluconazole doses ≤200 mg: JAKAFI XR 11 mg once daily
- Other CYP3A4 inhibitors: Monitor blood counts more frequently for toxicity and modify the JAKAFI XR dosage for adverse reactions if they occur
See Full Prescribing Information for further details on dose modifications and use in special populations.
cGVHD=chronic graft-versus-host disease.
Reference: 1. JAKAFI/JAKAFI XR Prescribing Information. Wilmington, DE: Incyte Corporation.
